Pegloticase (Krystexxa)



Provider Name (print)



PATIENT INFORMATION Refe	rral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal
Patient Name:	DOB: Patient Phone:
Patient Address:	Patient Email:
Allergies:	☐ NKDA Weight (lbs/kg): Height (in/cm):
Sex: ☐ M / ☐ F Date of Last Infusion: N	ext Due Date: Preferred Location:
DIAGNOSIS (Please provide ICD-10 code in space prov	ded)
Gouty arthropathy:	
Other: Description:	
DECLURED INFORMATION	LARORATORY ORDERS
REQUIRED INFORMATION	LABORATORY ORDERS
☑ G6PD Results & date	Obtain serum uric acid level prior to each infusion (or may use result obtained within 48 hrs prior to infusion).
Baseline unc acid level & date	Other:
THERAPY ADMINISTRATION & DOSING	
☐ Krystexxa 8mg IV every 2 weeks with weekly oral	PRE-MEDICATION ORDERS
methotrexate 15mg and daily folic acid 1mg ¹	☑ All premedication administered 30mins prior to infusion
☐ Methotrexate contraindicated and patient is on Krystexxa	
Monotherapy 8mg IV every 2 weeks	☐ Tylenol 500mg PO of 60 ☐ Solumedrol 125mg IV
✓ Monitor patient for hypersensitivity reaction for a period	of 60
minutes following each infusion	Other:
Begin weekly Methotrexate and Folic Acid 4 weeks prior to	tne
start of Krystexxa infusions.	NURSING
FREQUENCY (Choose one)	☑ Hold infusion and notify provider for:
☐ Every 2 weeks	 Uric acid level greater than 6 mg/dL for 2 consecutive
☐ Other:	treatments (lab orders below).
ADDITIONAL ORDERS	Patient has had more than 4 weeks between treatments (due to increased risk for a due real reaction)
	(due to increased risk for adverse reaction).Patient reports continued use of uric acid lowering agen
	(allopurinol, febuxostat, probenecid, etc.)
	Hypertension (170/90 or symptomatic)
	✓ Provide nursing care per Nursing Procedure, including
	Hypersensitivity Reaction Management Protocol and post-
	procedure observation
PROVIDER INFORMATION	
Preferred Contact Name:	Preferred Contact Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
	onal documentation required for processing and insurance approval)
Required Documentation: Patient demos, copy of front a	nd back of primary and secondary insurance, 2 most recent OVN including
•	
treatment failures or contraindications with colchicine, N	SAIDs, steroids, Febuxostat, Allopurinol, Probenecid. flares in 12 months, PD, UA level, CRP/ESR

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.

Date

Provider Signature